Read about the new Rx products featured in February 2017.
EUCRISAMARKETED BY:Anacor
INDICATION:The FDA has approved Anacor’s crisaborole ointment for the treatment of mild to moderate eczema in patients 2 years and older. Eucrisa is specifically indicated for the twice-daily treatment of atopic dermatitis.
DOSAGE FORM:Topical ointment: 2%
FOR MORE INFORMATION:anacor.com
SYNJARDY XRMARKETED BY:Boehringer Ingelheim and Eli Lilly
INDICATION:The FDA has approved Synjardy XR for the treatment of type 2 diabetes mellitus in adults. In combination with diet and exercise, the empagliflozin and metformin hydrochloride extended-release tablets are indicated to improve patients’ blood glucose level.
DOSAGE FORM:Tablets: 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, 25 mg/1000 mg
FOR MORE INFORMATION:synjardy.com
TRESIBAMARKETED BY:Novo Nordisk
INDICATION:The FDA has approved an expanded indication for Tresiba, the insulin degludec injection. The once-daily, long-acting basal insulin is now indicated for use in children as young as 1 year with type 1 or type 2 diabetes mellitus.
DOSAGE FORM:Injection: 100 U/mL and 200 U/mL
FOR MORE INFORMATION:tresiba.com